Longboard Pharmaceuticals, Inc. (LBPH) is a publicly traded company in the Unknown sector. Across all available filings, 4 corporate insiders have executed 16 transactions totaling $97.6M, demonstrating a bearish sentiment with -$97.6M in net insider flow. The most recent transaction on Sep 16, 2024 involved a sale of 4,200 shares valued at $133.6K.
No significant insider buying has been recorded for LBPH in the recent period.
No significant insider selling has been recorded for LBPH in the recent period.
Based on recent SEC filings, insider sentiment for LBPH is bearish with an Insider Alignment Score of 0/100 and a net flow of -$97.6M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Longboard Pharmaceuticals, Inc. (LBPH) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 4 insiders are actively trading LBPH stock, having executed 16 transactions in the past 90 days. The most active insider is Pharmaceuticals Inc Arena (Executive), who has made 2 transactions totaling $96.5M.
Get notified when executives and directors at LBPH file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Sep 16, 2024 | Kaye Randall | Executive | Sale | 4,200 | $31.81 | $133.6K | 10b5-1 |
| Sep 16, 2024 | Kaye Randall | Executive | Sale | 9,366 | $30.89 | $289.3K | 10b5-1 |
| Sep 16, 2024 | Kaye Randall | Executive | Option Exercise | 16,666 | $4.35 | $72.5K | 10b5-1 |
| Sep 16, 2024 | Kaye Randall | Executive | Sale | 1,900 | $34.04 | $64.7K | 10b5-1 |
| Sep 16, 2024 | Kaye Randall | Executive | Sale | 1,200 | $33.12 | $39.7K | 10b5-1 |
| Aug 12, 2024 | Kaye Randall | Executive | Sale | 6,191 | $35.03 | $216.9K | 10b5-1 |
| Aug 12, 2024 | Kaye Randall | Executive | Sale | 10,476 | $34.55 | $361.9K | 10b5-1 |
| Aug 12, 2024 | Kaye Randall | Executive | Option Exercise | 16,667 | $4.35 | $72.5K | 10b5-1 |
| Aug 12, 2024 | Robert Lind Kevin | Executive | Option Exercise | 2,217 | $4.20 | $9.3K | |
| Aug 12, 2024 | Robert Lind Kevin | Executive | Option Exercise | 80,265 | $3.12 | $250.4K | |
| Jun 25, 2024 | Kaye Randall | Executive | Sale | 100 | $20.87 | $2.1K | 10b5-1 |
| Feb 8, 2024 | Roberts Brandi | Executive | Award | 15,090 | $N/A | $0 | |
| Feb 8, 2024 | Kaye Randall | Executive | Award | 17,920 | $N/A | $0 | |
| Jan 25, 2024 | Inc Arena Pharmaceuticals | Executive | Sale | 3,978,540 | $24.25 | $96.5M | Large |
| Jan 23, 2024 | Kaye Randall | Executive | Purchase | 100 | $24.82 | $2.5K | 10b5-1 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 8 | $97.6M | 99.6% |
Exercise(M) | 4 | $404.7K | 0.4% |
Purchase(P) | 1 | $2.5K | 0.0% |
Award(A) | 2 | $0 | 0.0% |
Conversion(C) | 1 | $0 | 0.0% |
Insider selling pressure at Longboard Pharmaceuticals, Inc. has increased, with 4 insiders executing 16 transactions across all time. Total sales of $97.6M significantly outpace purchases of $2.5K, resulting in a net outflow of $97.6M. However, 63% of these transactions are pre-scheduled 10b5-1 plans, often used for tax planning or diversification rather than signaling negative outlook.